Financial analysis of Pfizer Inc. stock ahead of its earnings release. PFE faces significant headwinds from patent expiries, click for my updated look at the stock.

Weight loss treatments Mounjaro and Zepbound are the primary growth engines for Eli Lilly right now, but the company has another enormous opportunity that's getting very little attention.

Zentalis Pharmaceuticals Inc (ZNTL) stock saw a modest uptick, ending the day at $2.3 which represents a slight increase of $0.04 or 1.77% from the prior close of $2.26. The stock opened at $2.25 and ...

External hiring of finance chiefs hit a 10-year high in 2024, according to Crist Kolder Associates' annual report.

Fortune 500 companies are hiring external CFOs at record levels, with 47.1% of appointments in 2024 coming from outside.

In the tough market conditions last year, investors and big pharma companies were more likely to place their bets on later, clinical-stage companies. But local biotech leaders see signs of change in ...

Bristol Myers Squibb plans to release initial late-stage trial data on Cobenfy in Alzheimer’s-related psychosis during the ...

The updated guidance, which was largely driven by lower-than-anticipated sales of GLP-1 blockbusters Mounjaro and Zepbound, ...

Eli Lilly & Co.’s fourth-quarter revenue fell short of analysts’ estimates as the drugmaker struggled to forecast demand for ...

Eli Lilly cut its 2024 revenue guidance, saying demand for its obesity and diabetes drugs had not met its lofty expectations. Eli Lilly expects about $3.5 billion in revenue for its diabetes ...

Eli Lilly LLY2.29%increase; green up pointing triangle cut its outlook for fourth-quarter revenue as the market for drugs that increase insulin levels grew slower than expected, but the company ...

Eli Lilly can’t seem to recover from its GLP-1 stumble. Once again, the drugmaker reported sales of its blockbuster GLP-1 medicines Zepbound and Mounjaro that missed Wall Street estimates. It was the ...